GENE ONLINE|News &
Opinion
Blog

2021-06-18| ChinaPolicySpecial

From Great Challenges to Great Opportunities: An Outlook on US-China Biotech Relationships

by Daniel Ojeda
Share To
The US-China relationship is under a lot of stress following a trade war and a global pandemic. For companies, these are crucial markets that offer great opportunities but also great challenges.
During the BIO Digital 2021, a panel of policy experts discussed their opinions and views on how the US-China relationships will affect biotechnology companies in 2021. 

GO Prime with only $1.49 now

LATEST
APAC Leading the Industry in Adoptive Cell Therapy – Trials, Economic Growth, and Pioneering Companies
2024-06-24
Taiwan’s Biotech and Pharma Delegation: Innovations Take Center Stage at BIO 2024
2024-06-21
Breaking Ground in Alzheimer’s with 10 Cutting-Edge Treatments Paving the Way in 2024
2024-06-21
Merck Buys EyeBio for $3B and Shares Global Policy Perspectives During BIO in San Diego
2024-06-20
Johnson & Johnson’s Bispecific Antibodies for Atopic Dermatitis and Talks of Biotech Partnerships at BIO 2024
2024-06-20
Merck’s KEYNOTE-522 Success; BMS Licenses PRX019, Prothena Gets $80M
2024-06-19
SINBON and MAKALOT partner to drive cross-industry textile wearable adoption
2024-06-19
EVENT
Scroll to Top